Memorandum on Participation of Pharmaceutical Company MSD in BIO4 Campus Signed

The prime minister of the Government of Serbia, Ana Brnabic, has signed the Memorandum of Understanding which is important for the future research center BIO4 Campus in Serbia, with the senior vice president of the pharmaceutical company Merck Sharp and Dohme (MSD), Cyril Schiever, the Government of Serbia announced.

Brnabic said that the Memorandum of Understanding pertained to the participation of MSD in BIO4 Campus.

– This is an extremely important reference which will help us to bring other biopharmaceutical companies, as well as research and development institutes in the coming weeks and months to the BIO4 Campus and to together build a center for future research in these field for this part of Europe – she said.

As she reminded, since 1996, MSD has been very active in Serbia and cooperates with the National Health Insurance Fund in order to secure the most modern and innovative therapies for the treatment of our patients, with the oncology patients being the most difficult cases.

Schiever explained that the signed agreement would enable MSD, which provides innovative care and possibilities of treatment and healing of patients, to work on a research project within the BIO4 Campus.

– BIO 4 Campus is a very important project for Serbia and the region, and we expect it to be very important on the European level as well – he estimated and added that MSD wanted to reach a better understanding of the way that care is given to patients, which entails quick and efficient diagnostics.

– We want to achieve an improvement of the efficiency of the health system. What’s challenging in these times is efficient care and that is something that BIO4 Campus will contribute to as a research center – Schiever said.

Vlada Republike Srbije

Merck Sharp & Dohme d.o.o. Beograd

Republički fond za zdravstveno osiguranje Beograd

Government of Serbia

Merck Sharp and Dohme MSD

National Health Insurance Fund

Ana Brnabić

Cyril Schiever

BIO4 Campus

pharmaceutical company

Memorandum of Understanding between the Government of Serbia and MSD

treatment of oncology patients